cobas® Influenza A/B Assay

Product image for cobas® Influenza A/B Assay

Give an early, accurate flu diagnosis

Influenza affects 5-10% of adults and 20-30% of children each year.1 Whether it’s a typical flu season, or a worst-case pandemic, testing and screening for influenza A and B can help protect patients.

Get the speed and reliability you need to support a timely, accurate diagnosis with the cobas® Influenza A/B assay. A multi-plex real-time PCR assay, cobas® Influenza A/B differentially detectes both influenza A and influenza B in ~20 minutes.



cobas® Influenza A/B performance

The fast, reliable cobas® Influenza A/B test enables healthcare professionals to support a timely, accurate diagnosis.

With the maximum specificity and sensitivity of the cobas® Liat® influenza test results there is no need for test confirmation.
With the maximum specificity and sensitivity of the cobas® Liat® influenza test results there is no need for test confirmation.


The cobas® Liat® PCR System vs. Conventional methods
The cobas® Influenza A/B test provides definite results within 20 minutes – much faster than conventional methods.
The cobas® Influenza A/B test provides definite results within 20 minutes – much faster than conventional methods.
Simplified PCR workflows thanks to cobas® Liat® System

The cobas® Liat® System consisting of the cobas®  Influenza A/B Nucleic acid test 
and the cobas® Liat® Analyzer delivers lab-quality test results in about 15 minutes, requiring a hands-on time of less than a minute.

The Influenza A/B test assay simplifies PCR workflows.
Sample

The provided transfer pipette helps adding the patient sample to the assay tube.

Scanning the assay tube’s barcode is part of the three-step workflow.
Scan

The cobas® Liat® Analyzer´s built-in barcode reader scans the barcode on the assay tube sleeve and the patients sample ID.

The cobas® Influenza A/B test assay gets inserted in the analyzer.
Start

After inserting the assay tube, the Analyzer automatically begins to run the test. About 15 minutes later, definitive results appear on the screen.

Intended use

 

The cobas® Influenza A/B Nucleic acid test for use on the cobas® Liat® System, is an automated multiplex real-time RT-PCR assay for the rapid in vitro qualitative detection and discrimination of Influenza A virus and Influenza B virus RNA in nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors.

The test is intended for use as an aid in the differential diagnosis of Influenza A and Influenza B in humans and is not intended to detect Influenza C.

The cobas® Liat® System is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Registration status

CE-IVD, FDA 510(k) cleared, CLIA waived

Package inserts

Access package inserts through your country’s Roche Diagnostics Website.

References

 

  1. World Health Organization. Vaccines against influenza. WHO position paper – November 2012 Weekly Epidemiol Record. 2012;87(47):461–76. 
  2. cobas® Influenza A/B [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2015. 

Related systems

cobas® Liat® System image

cobas® Liat® System

The cobas® Liat® System is a fast, easy-to-use, compact PCR system designed for on-demand testing in point-of-care* settings such as physician clinics, pharmacy, and...

More